Atacand (Chronic Heart Failure)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Upcoming Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 12
3.2 Prognosis 16
3.3 Quality of Life 16
3.4 Symptoms 17
4 Disease Management 19
4.1 Treatment Overview 20
4.1.1 Pharmacological Treatments 22
4.1.2 Mechanical Devices 28
5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 29
6 Atacand (candesartan) 32
6.1 Overview 32
6.2 Efficacy 32
6.3 Safety 33
6.4 SWOT Analysis 34
6.5 Forecast 35
7 Appendix 36
7.1 Bibliography 36
7.2 Abbreviations 38
7.3 Methodology 40
7.4 Forecasting Methodology 40
7.4.1 NYHA Class Segmentation of Total Prevalent CHF Population 40
7.4.2 Diagnosed CHF Population 41
7.4.3 Drug-Treated CHF Population 42
7.4.4 Patient Population Breakdown: HF-REF versus HF-PEF 42
7.4.5 Treatment of HF-REF versus HF-PEF 42
7.4.6 General Pricing Assumptions 43
7.4.7 Drugs Assumptions 44
7.4.8 Generic Erosion 44
7.5 Physicians and Specialists Included in this Study 45
7.6 Survey of Prescribing Physicians 46
7.7 About the Authors 47
7.7.1 Author 47
7.7.2 Global Head of Healthcare 47
7.8 About GlobalData 48
7.9 Disclaimer 48